XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation (Tables)
 12 Months Ended
Feb. 03, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan
The compensation expense for these plans was as follows (in thousands):

Fiscal Year Ended
February 3,
2024
(53-weeks)		January 28,
2023
(52-weeks)		January 29,
2022
(52-weeks)
Stock-based compensation expense by type:
Stock options
$220 $155 $174 
Restricted stock units
5,026 6,204 5,111 
Employee stock purchases
358 358 199 
Director deferred compensation
105 94 56 
Total stock-based compensation expense
5,709 6,811 5,540 
Income tax benefit recognized
1,183 1,562 1,316 
Stock-based compensation expense, net of income tax
$4,526 $5,249 $4,224 
Share-based Compensation, Stock Options, Activity
Activity for our option plans during Fiscal 2024 was as follows:
Number of
Shares		Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Term
(Years)		Aggregate
Intrinsic
Value
($000’s)
Options outstanding at January 28, 2023100,951 $38.24 4.03$2,859 
Granted8,188 58.38 
Exercised(40,044)37.87 
Forfeited, cancelled or expired— — 
Options outstanding at February 3, 202469,095 $40.83 4.20$2,003 
Exercisable at February 3, 202469,095 $40.83 4.20$2,003 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
Details of stock options granted and the assumptions used in the option pricing model were as follows:

Fiscal Year Ended
February 3,
2024
(53-weeks)		January 28,
2023
(52-weeks)		January 29,
2022
(52-weeks)
Stock option grants211
Stock option grant dateMarch 31, 2023March 30, 2022March 22, 2021
Total stock options granted8,1887,2124,384
Exercise price$58.38$46.22$76.04
Fair value of stock options$26.87$21.46$39.73
Expected term5.73 years4.59 years4.63 years
Expected volatility53.76%65.05%64.75%
Risk-free interest rate3.57%2.44%0.77%
Dividend yield1.71%2.28%0.00%
Intrinsic value of stock options exercised (in millions)$1.1$1.1$2.7
Total cash received by participants from stock options exercised (in millions)$2.6$3.5$4.7
Unamortized compensation expense at fiscal period end$—$—$—
Schedule of Share-based Compensation, Restricted Stock Units Award Activity
The following table summarizes the restricted stock unit awards activity under all our plans during Fiscal 2024:

RSUsPSUsTotals
Number of
Awards		Weighted
Average
Grant-Date
Fair Value		Number of
Awards		Weighted
Average
Grant-Date
Fair Value		Number of
Awards		Weighted
Average
Grant-Date
Fair Value
Nonvested at January 28, 2023464,833 $28.62 72,470 $55.48 537,303 $32.24 
Granted92,374 57.86 39,567 58.38 131,941 58.02 
Vested(178,193)21.00 — — (178,193)21.00 
Forfeited, cancelled or expired(37,788)33.69 — — (37,788)33.69 
Nonvested at February 3, 2024341,226 $39.95 112,037 $56.50 453,263 $44.04 
Details of RSUs granted and vested were as follows:

Fiscal Year Ended
February 3,
2024
(53-weeks)		January 28,
2023
(52-weeks)		January 29,
2022
(52-weeks)
Intrinsic value of vested awards (in millions)$10.5$7.3$10.5
Intrinsic value of outstanding and unvested awards (in millions)$31.5$35.5$35.2
Unrecognized compensation expense at fiscal period end (in millions)$4.9$7.5$7.0
Estimated weighted average period unrecognized compensation expense expected to be recognized1.7 years1.7 years2.0 years
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity Our employee purchases of common stock and the average price per share through the ESPP, as well as the assumptions used in the option pricing model were as follows:
Fiscal Year Ended
February 3,
2024
(53-weeks)		January 28,
2023
(52-weeks)		January 29,
2022
(52-weeks)
Shares purchased34,40532,58614,447
Average price per share$36.70$48.33$50.01
Weighted average fair value at date of grant$13.32$14.33$14.33
Expected life (years)0.250.250.25
Average expected volatility54.5%52.1%52.1%
Average risk-free interest rate9.16%3.55%0.28%
Average dividend yield2.06%1.86%1.26%
Schedule of Number of Directors in Deferred Plan The number of Directors who participated in the Deferred Plan as well as the number of shares deferred each year were as follows:
Fiscal Year Ended
February 3,
2024
(53-weeks)		January 28,
2023
(52-weeks)		January 29,
2022
(52-weeks)
Number of directors that deferred all or a portion of their fees112
Shares deferred under the Deferred Plan2,0731,832729